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Abstract: This study aims to validate the oncologic outcomes of
anastomotic leakage (AL) after laparoscopic total mesorectal excision
(TME) in a large multicenter cohort.
The impact of AL after laparoscopic TME for rectal cancer surgery
has not yet been clearly described.
This was a multicenter retrospective study of 1083 patients who
underwent laparoscopic TME for nonmetastatic rectal cancer (stage
0–III). AL was defined as an anastomotic complication within 30 days
of surgery irrespective of requiring a reoperation or interventional
radiology. Estimated local recurrence (LR), disease-free survival
(DFS), and overall survival (OS) were compared between the
leakage group and the no leakage group using the log-rank method.
Multivariate Cox-regression analysis was used to adjust confounding for
survival.
The incidence of AL was 6.4%. Mortality within 30 days of surgery
occurred in 1 patient (1.4%) in the leakage group and 2 patients (0.2%)
in the no leakage group. The leakage group showed a higher LR rate
(6.4% vs 1.8%, P¼ 0.011). Five-year DFS and OS were significantly
lower in the leakage group than the no leakage group (DFS 71.7% vs
82.1%, P¼ 0.016, OS 81.8% vs 93.5%, P¼ 0.007). Multivariate
analysis showed that AL was an independent poor prognostic factorrk, MD, PhD, Min ,
Seung Hyuk Baik, MD, PhD
AL after laparoscopic TME was significantly associated with an
increased rate of LR, systemic recurrence and poor OS.
(Medicine 94(29):e1202)
Abbreviations: AL = anastomotic leakage, BMI = body mass
index, CRM = circumferential resection margin, CT = computed
tomography, DFS = disease-free survival, LR = local recurrence,
MRI = magnetic resonance imaging, OS = overall survival, PET =
positron emission tomography, TME = total mesorectal excision.
INTRODUCTION
A nastomotic leakage (AL) is a major cause of postoperativemortality and morbidity after rectal cancer surgery, and the
incidence of AL ranged from 2.5% to 20%.1–11 After the
introduction of total mesorectal excision (TME) and spread
of this technique to a standard procedure for the management of
rectal cancer, it is debatable whether TME in itself results in
higher rates of AL. With an increasing proportion of sphincter
preserving procedures,12 more patients are exposed to the risk of
this serious complication.
There are inconsistent data of the effect of AL on onco-
logic outcomes after rectal cancer surgery. Some authors have
demonstrated that AL is associated with an increased rate of
local recurrence (LR) or a reduced rate of overall survival
(OS).2–5,13 In contrast, other investigators reported that the rate
of local or distant recurrence remained unaffected in patients
with AL.7–10 Notably, most of these studies on the impact of AL
after rectal cancer surgery were based on patients who under-
went open surgery.
Laparoscopic surgery has been increasingly performed for
the treatment of rectal cancer. Although recent randomized trials
demonstrated short-term benefits or mid-term oncologic safety of
laparoscopic rectal cancer surgery, the AL rate between open and
laparoscopic surgeries was not changed.14–16 It was known that
the laparoscopic surgery group showed less immunosuppressed
following surgery,17,18 so the influence of AL on long-term
outcomes might be different between open and laparoscopic
surgeries. However, to our knowledge, the oncologic impact
of AL for patients who underwent laparoscopic TME has never
been investigated on a large-scale study.
Recently, the Korean Laparoscopic Colorectal Surgery
Study Group collected clinical data from various hospitals
and reported that a low tumor height, male sex, advanced stage,irings, preoperative chemoradiotherapy,
ing were independently associated with
phincter-saving TME for rectal cancer.19
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The results of previous study demonstrated that technical
difficulties are still associated with AL in laparoscopic TME
for rectal cancer. However, the long-term oncologic impact of
AL was not evaluated.
To investigate this issue, we collected another set of
patients who underwent laparoscopic TME. Thus, the aim of
this study was to evaluate the impact of AL on long-term
oncologic outcomes after laparoscopic TME for rectal cancer.
MATERIALS AND METHODS
Study Population
As similar to a previous multicenter study, The Korean
Laparoscopic Colorectal Surgery Study Group asked individual
hospitals to participate in this study. Consecutive patients who
performed laparoscopic proctectomy for rectal cancer (patho-
logic stage 0–III) from January 2006 to December 2009 were
collected from 4 hospitals. A total of 1083 patients who had
undergone laparoscopic TME and anastomosis for rectal cancer
(within 15 cm of the anal verge) were enrolled and composed of
the data set of this analysis.
All patients’ preoperative, operative, and postoperative
data including survival outcomes were collected using a com-
mon menu driven excel file that incorporated precise coding
instructions. Perioperative outcomes included age, sex, body
mass index (BMI), American Society of Anesthesiologists
(ASA) grade, receipt of preoperative chemoradiotherapy, pre-
operative serum albumin and hemoglobin levels, operative time,
perioperative transfusion information, tumor height, type of
anastomosis, diverting stoma formation, histopathology details
(pT stage, pN stage, pM stage, tumor diameter, circumferential
resection margin [CRM], and distal resection margin), hospital
stay, morbidity, postoperative chemotherapy and radiotherapy,
recurrence site, recurrence date, and survival and deceased
date. The sixth edition of the tumor node metastasis (TNM)
classification was used to determine the TNM stage in this
study. This study was approved by our Institutional Review
Board (3-2015-0121).
Clinical Staging and Preoperative
Chemoradiotherapy
Patients were staged with either a combination of appro-
priate imaging studies such as chest radiography, transrectal
ultrasonography, pelvic magnetic resonance imaging (MRI),
abdominopelvic computed tomography (CT), chest CT, or
18-FDG positron emission tomography (PET) before the
operation.
In general, preoperative chemoradiotherapy was recom-
mended to patients with locally advanced rectal cancer who
had a clinical stage T3 or T4 and/or Node (þ). However, the
decision for preoperative chemoradiotherapy was left to each
institution’s discretion. Radiotherapy consisted of a total dose of
45 Gy delivered to the pelvis in 25 fractions, followed by a 5.4 to
9 Gy boost to the primary tumor in 3 to 5 fractions given over
5 weeks. The clinical target volume was demarcated as follows:
the superior border of the whole pelvis was placed at the
lumbosacral junction, the inferior border was placed at the
inferior margin of the obturator foramen or 3 cm below the lower
margin of the gross tumor, the lateral field border extended 1.5 cm
outside the bony pelvis, the anterior border of lateral fields was
Kang et al3 cm anterior to the gross tumor and shaped to include the internal
iliac lymph nodes, and the posterior border of lateral fields
extended to encompass all the sacral vertebra. The area that
2 | www.md-journal.comreceived the prescription dosewas specified at the isocenter of the
gross tumor volume; the 3-field treatment plan comprised of a
6-MV photon posterior–anterior field, and 6- or 10-MV photon
opposed lateral fields with wedges of 458. 5-Fluorouracil (5-FU)
400mg/m2/day and leucovorin (LV) 20mg/m2/day for 5 days on
days 1 to 5 and days 29 to 33 during radiotherapy were delivered
with continuous infusion as preoperative chemotherapy regi-
mens. Surgery was performed 6 to 10 weeks after the completion
of preoperative chemoradiotherapy. In general, postoperative
adjuvant chemotherapy was then added for up to 4 cycles of
intravenous 5-FU and LV.
Surgery and Morbidity
Patients received a mechanical bowel preparation with
polyethylene glycol solution the day before surgery. Prophy-
lactic antibiotics were administered just before making the skin
incision. Although postoperative care varied slightly across
institutions, most surgeons had established a similar protocol
for postoperative management and surveillance. Technical pro-
cedures for laparoscopic TME, anastomosis technique, creation
of a diverting stoma, and drain insertion were already described
in a previous study and these procedures were constant in this
study.19
Postoperative complications were defined as adverse
events that occurred within 30 days after surgery. The defi-
nition of AL included the discharge of pus or bowel contents
through the indwelling drain, pelvic abscess, and local or
generalized peritonitis. These criteria included all patients
who developed any clinical sign of dehiscence of the anasto-
mosis, regardless of whether a reoperation or any other inter-
vention was required. The diagnosis of AL was usually
confirmed by clinical findings, contrast radiography (X-ray
or CT scan), or laparotomy.
Postoperative Adjuvant Chemoradiotherapy
After recovery from surgery, postoperative adjuvant che-
moradiotherapy was recommended to patients diagnosed as
stage II or III rectal cancer who did not undergo preoperative
chemoradiotherapy. For the postoperative adjuvant chemora-
diotherapy, adjuvant chemotherapy started within 4 to 8 weeks
after curative resection. 5-FU 400mg/m2/day and LV 20mg/m2/
day for 5 days were delivered with continuous infusion for 6
cycles with 4-week intervals. Radiotherapy was started at the
3rd cycle of chemotherapy for 5 cycles, and the total amount of
the radiation dose was 50.4 to 54 Gy. The radiation technique
and boundary were the same as the preoperative chemora-
diotherapy. In cases of stage III, other regimens such as FOL-
FOX or FOLFIRI regimen were used without postoperative
radiotherapy according to the policy of each institution.
Follow-Up
All of the patients had postoperative follow-up visits
every 2 to 3 months for 3 years. After 3 years, follow-up visits
were reduced to every 6 months until 5 years, and annually
thereafter. A physical examination, serum carcinoembryonic
antigen level measurement, chest radiography, bone scintigra-
phies, abdominopelvic CT scans, chest CT, pelvic MRI, or 18-
FDG PET scan was performed as indicated according to each
institution’s policy. All patients undergoing surgery were
received close follow-up. Patient follow-up lasted until the
Medicine  Volume 94, Number 29, July 2015cut-off date (June 2014), or when the patient died. The median
follow-up period for all the patientswas 54months (range, 1.0–
93.0 months).
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TABLE 1. Patient Characteristics
Leakage Group
(N¼ 69), N (%)
No Leakage Group
(N¼ 1014), N (%)
P Value
Gender Male 52 (75.4) 622 (61.3) 0.020
Female 17 (24.6) 392 (38.7)
Age, yr Mean  SD 61.8  8.4 61.9 10.9 0.873
BMI, kg/m2 MeanSD 24.1 3.4 23.6 3.0 0.213
ASA grade I 41 (59.4) 589 (58.1) 0.758

II 25 (36.2) 391 (38.6)
III 3 (4.3) 34 (3.4)
Preoperative Hg level, g/dL MeanSD 12.7 1.6 12.9 1.7 0.345
Preoperative albumin level, g/dL MeanSD 4.1 0.4 4.1 0.5 0.951
Neoadjuvant chemoradiotherapy 18 (26.1) 221 (21.8) 0.405
Tumor height, cm MeanSD 7.8 3.0 9.3 3.6 <0.001
ASA¼American Society of Anesthesiologists; BMI¼ body mass index; SD ¼ standard deviation.
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LR was defined as any recurrent tumor growth within the
pelvic cavity or perineal area confirmed by clinical, radiologi-
cal, or pathological evidence. In patients with a suspected LR,
pelvic MRI was often performed. For histological confirmation,
an imaging-guided biopsy was performed, when possible.
However, biopsy confirmation was possible in all but a small
number of cases. Overall LR rates are given as the sum of
isolated LR and LR with concomitant systemic metastases.
Systemic recurrence is defined as recurrence outside the pelvis.
Statistical Analysis
All statistical analyses were performed using SPSS soft-
ware, version 20.0 (SPSS, Chicago, IL). Categorical variables
were analyzed using the Chi-squared test or Fisher’s exact test,
and continuous variables were analyzed using the Student t test.
OS was defined from the date of surgery to the date of death or
last follow-up. Disease-free survival (DFS) was defined from
the date of surgery to the date of detection of recurrence, last
follow-up or death. Differences in survival and recurrences
between groups were compared using the Kaplan–Meier
method and tested with the log-rank test. For cumulative LR
calculations, duration of follow-up was calculated from the day
of surgery and analyzed by the reverse Kaplan–Meier
method.20 All variables P< 0.05 on univariate analysis were
initially entered into the multivariate analysis. Factors associ-
ated with DFS and OS were analyzed by a Cox-proportional
hazards regression analysis done by a forward stepwise selec-
tion of variables. P< 0.05 was considered statistically signifi-
cant.
RESULTS
Among 1083 enrolled patients, AL occurred in 69 patients
(6.4%). The AL of the patients was categorized into the leakage
group, and the others were categorized into the no leakage
group.

Fisher’s exact test.Clinicopathological Characteristics
Clinical characteristics of the patients in the 2 groups
are listed in Table 1. No significant difference was observed
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.in age, BMI, ASA grade, preoperative hemoglobin and
albumin level, and rate of preoperative chemoradiotherapy.
However, the leakage group showed male predominance
and lower tumor height compared with the no leakage group
(75.4% vs 61.3%, P¼ 0.020, 7.8 cm vs 9.3 cm, P< 0.001,
respectively).
Perioperative Outcomes
Perioperative outcomes of surgery are listed in Table 2.
Operation type was not different between the 2 groups. Mean
operation time was significantly longer in the leakage group
compared with the no leakage group (P¼ 0.006). Rate of
performing fecal diversion was similar between the 2 groups.
Blood transfusion during the operation or the day of operation
was more commonly performed in the leakage group (10.1% vs
2.9%, P¼ 0.006). Length of hospital stay was significantly
longer in the leakage group compared with the no leakage
group (30.1 days vs 9.9 days, P< 0.001).
No significant difference was observed in tumor size, (y)p
Stage, distal resection margin, and CRM involvement rate.
However, CRM status was available in 784 patients (72.4%).
The rate of performing postoperative radiotherapy was similar
between the 2 groups. There was no difference of chemotherapy
regimen between the 2 groups. There was 3 postoperative
mortalities (1 in the leakage group and 2 in the no leakage
group, P¼ 0.179)
Oncologic Outcomes
The 5-year DFS and OS was significantly lower in the
leakage group than the no leakage group (DFS 71.7%
vs 82.1%, P¼ 0.016, OS 81.8% vs 93.5%, P¼ 0.007)
(Figure 1). The overall 5-year cumulative LR rate was 6.4%
in the leakage group and 1.8% in the no leakage group
(P¼ 0.011) (Figure 2).
For DFS, age, preoperative hemoglobin level, preoperative
chemoradiotherapy, tumor height, perioperative transfusion,
tumor size, stage, CRM, postoperative chemotherapy, and
AL were proved to be significant prognostic factors in uni-
variate analysis (Table 3). Among them, age, preoperative
chemoradiotherapy, stage, and AL remained as prognostic
www.md-journal.com | 3
TABLE 2. Perioperative Clinicopathological Outcomes
Leakage Group
(N¼ 69), N (%)
No Leakage Group
(N¼ 1014), N (%) P Value
Operation type AR 2 (2.9) 93 (9.2) 0.172
LAR 58 (84.1) 773 (76.2)
CAA 9 (13.0) 148 (14.6)
Operation time, min MeanSD 245.4 88.4 216.8 82.8 0.006
Fecal diversion 14 (20.3) 264 (26.0) 0.290
Transfusion at operation day 7 (10.1) 29 (2.9) 0.006

Length of stay, d MeanSD 30.1 62.0 9.9 6.1 <0.001
Tumor size, cm 4.2 2.0 3.8 1.9 0.149
(y)p Stage 0 and I 19 (27.5) 369 (36.4) 0.328
II 24 (34.8) 302 (29.8)
III 26 (37.7) 343 (33.8)
CRM Involved (1 mm) 6 (8.7) 42 (4.1) 0.209
Noninvolved (>1 mm) 46 (66.7) 690 (68.0)
Unknown 17 (24.6) 282 (27.8)
DRM Positive 0 (0) 3 (0.3) 0.523

Negative 64 (92.8) 957 (94.4)
Unknown 5 (7.2) 54 (5.3)
Length of DRM, cmy MeanSD 2.2 1.7 2.7 1.7 0.072
Postoperative radiation Tx. 11 (15.9) 204 (20.1) 0.400
Postoperative chemotherapy None 24 (34.8) 375 (37.0) 0.821
IV 5-FU/Oral 5-FU 40 (58.0) 551 (54.3)
FOLFOX/FOLFIRI 5 (7.2) 88 (8.7)
Mortality Within 30 d 1 (1.5) 2 (0.2) 0.179

5-FU ¼ 5-fluorouracil; AR¼ anterior resection with double stapled anastomosis; CAA¼ coloanal anastomosis; CRM¼ circumferential resection
margin; DRM¼ distal resection margin; LAR¼ low anterior resection with double stapled anastomosis.
Kang et al Medicine  Volume 94, Number 29, July 2015factors in multivariate analysis. For OS, age, ASA grade,
preoperative hemoglobin level, stage, CRM, and AL were

Fisher’s exact test.
yOf the 1008 patients who were available for the data.proved to be significant prognostic factors in univariate analysis
(Table 3). Among them, age, ASA grade, stage, CRM, and
AL remained as significant factors associated with OS in
FIGURE 1. Five-year overall survival (OS) and disease-free survival (D
leakage group showed poor 5-year OS (A) and DFS (B) than the no
4 | www.md-journal.commultivariate analysis. In brief, multivariate analysis showed
that AL was an independent poor prognostic factor for DFS and
OS (hazard ratio [HR]¼ 1.6; 95% confidence intervals [CI]:
1.0–2.6; P¼ 0.042, HR¼ 2.1; 95% CI: 1.0–4.2; P¼ 0.028,
respectively) (Table 4).
FS) between the leakage group and the no leakage group. The
leakage group (P<0.05, for all).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 2. Cumulative 5-year local recurrence rate between the
leakage group and the no leakage group. Cumulative 5-year local
recurrence rate was significantly higher in the leakage group than
the no leakage group (the leakage group vs the no leakage group;
Medicine  Volume 94, Number 29, July 2015DISCUSSION
This multicenter analysis demonstrated that AL after
laparoscopic TME with sphincter preservation in patients with
rectal cancer resulted in inferior oncologic outcomes with
respect to DFS and OS.
Laparoscopic surgery in management of rectal cancer
could provide an enhanced benefit to patients in terms of
postoperative early recovery and reduced pain.21 Long-term
oncologic outcome of laparoscopic rectal cancer surgery is
recently reported to be comparable to that of open surgery.14,22
Thus, application of laparoscopy would be increased for rectal
cancer surgery. However, in a study comparing open, laparo-
scopic, and robotic surgeries for mid and low rectal cancers, the
AL rate was significantly higher in the laparoscopic surgery
group than the other 2 groups.23 It is argued that difficulties in
perpendicular transection of the rectum and increased number
of linear stapler firings in laparoscopic surgery might result in
the high incidence of AL.19,23–25 Currently, the impact of AL on
LR or systemic recurrence after laparoscopic TME has not been
evaluated in a large-scale study design. Most previous studies
focusing on the oncologic outcomes after AL in rectal cancer
included patients who underwent open surgery. As far as we
know, the strength of our study is that this study might be one of
the first studies focusing on this issue.
The impact of AL on long-term oncologic outcomes for
patients with rectal cancer is contradictory. In a large-scale
population-based cohort study, AL did not result in an increased
6.4% vs 1.8%, P¼0.011).LR rate.8 In a single center-based study, clinical leakage was not
associated with time to LR, DFS, or OS.7,10 In contrast, many
investigators reported an increased LR rate or reduced OS rate
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.after AL.2–6,13 One of the possible explanations for this dis-
crepant oncologic effect of AL after rectal cancer surgery might
be the fact that the definition of AL has not been standar-
dized.8,26 It is well known that delayed leakage, such as
rectovaginal fistula, pelvic abscess, or radiologic detected sub-
clinical leakage showed different clinical manifestations com-
pared with AL occurring in immediate postoperative periods.27
Although the International Study Group of Rectal Cancer
suggested the 3 grading system of AL in 2010,28 most previous
studies used their own definition of AL. For example, Ptok et al3
divided AL patients into ‘‘surgically treated leakage’’ and
‘‘nonsurgically treated leakage’’ and compared these 2 groups
with a ‘‘no leakage group.’’ Smith et al7 defined clinical leakage
as an anastomotic event requiring intervention or interventional
radiology within 60 days of surgery. Such differences could
impact the association of AL with recurrence or survival.
In the present study, the leakage group showed worse
prognosis in LR, systemic recurrence, and OS. The underlying
mechanism of the poor oncologic impact of AL cannot be fully
accounted for by the result of our study. Walker et al6 speculated
that the poor oncologic outcomes of patients with AL may be
attributed not only to the higher rate of morbidity but also to
some unknown inflammation-related immunologic stimulation
of cancer recurrence. Recently, Salvans et al29 reported that
postoperative peritoneal fluid from infected patients enhanced
both cell migration and cell invasion capacities of cancer cell
lines, which might be one of the possible mechanisms respon-
sible for the association between postoperative peritoneal infec-
tion and tumor recurrence. Another potential reason is that,
considering the presence of viable tumor cells in the bowel
lumen of patients with rectal cancer,30,31 AL may lead to
extraluminal implantation of exfoliated cancer cells remaining
in the bowel lumen.3
Significant changes were introduced in the management of
colorectal cancer in terms of surgical technique and adjuvant
therapy. The survival rate of colorectal cancer has gradually
improved since 1975 to 2006 in the USA.32 A single center-
based study by Smith et al7 demonstrated no difference of
oncologic results in patients with an AL compared with those
without it. In detail, they included patients treated from 1991 to
2010. Thus, different treatment strategies owing to a long span
of enrolled periods are inevitable, which might be act as a bias.
In addition, as the authors commented, their study had possi-
bilities of underpowered analysis due to relatively few events of
AL and LR. When we analyzed the impact of AL on oncologic
outcomes, one of the main limitations was that the small number
of AL patients hindered it as a meaningful parameter of multi-
variate analysis for survival. Our large-scale multicenter
analysis enrolled recently treated patients in a short span from
2006 to 2009. The treatment modalities for rectal cancer during
the study periods were already well established. Also preopera-
tive chemoradiotherapy, TME, and postoperative adjuvant
treatment were included. In addition, this study has strengths
in including adequate events of AL to evaluate the primary
end point.
Nevertheless, this retrospective study design still has
several potential limitations. In this large-scale multicenter
evaluation, the AL rate was 6.4%, which was almost similar
to the results of a previous study.19 As described in our earlier
observational study, it is impossible to obtain the actual AL rate
including clinical leakage and subclinical leakage, because
Impact of Anastomotic Leakage on Oncologic Outcomesradiologic studies such as barium enema before closure of a
stoma were not routine procedures in our study cohort.19 In this
study, the diagnosis of AL was dependent on clinical
www.md-journal.com | 5
TABLE 3. Univariate Analysis of Prognostic Factors
N 5-yr DFS, % P Value 5-yr OS, % P Value
Gender Male 674 81.4 0.927 93.0 0.768
Female 409 81.6 92.5
Age, yr <70 794 83.5 0.003 94.3 <0.001
70 289 74.4 87.7
BMI, kg/m2 <25 734 81.5 0.973 93.0 0.997
25 349 81.5 92.4
ASA grade I 630 81.5 0.547 95.4 0.007
II 416 82.4 89.4
III 37 71.9 89.6
Preoperative Hg level, g/dL <12 197 74.7 0.009 87.8 0.019
12 886 82.9 93.7
Neoadjuvant chemoradiotherapy Yes 239 77.6 0.022 90.7 0.075
No 844 82.6 93.4
Tumor height, cm Low (0–5) 188 78.6 0.027 95.2 0.077
Mid (5.1–10) 553 79.8 90.6
Upper (10.1–15) 342 85.7 94.9
Operation type AR 95 82.9 0.155 93 0.454
LAR 831 82.2 92.2
CAA 157 76.6 95.7
Operation time, min <300 901 82.4 0.093 93.6 0.069
300 182 77.3 89.4
Fecal diversion Yes 278 77.9 0.100 92.4 0.422
No 127 82.8 92.9
Perioperative transfusion No 1047 81.9 0.022 93.3 0.157
Yes 36 68.9 81.3
Tumor size, cm <5 755 83.5 0.022 93.4 0.412
5 328 76.4 91.1
TNM stage Stage 0 and I 388 91.7 <0.001 96.7 <0.001
Stage II 326 87.2 95.9
Stage III 369 65.4 85.5
CRM Involved (1 mm) 48 63.5 <0.001 76.0 <0.001
Noninvolved (>1 mm) 736 80.7 93.0
Unknown 299 86.4 95.1
DRM Positive 3 50 0.261 100 0.139
Negative 1021 81.1 93.0
Unknown 59 87.9 89.6
Postoperative radiation Tx. Yes 215 77.3 0.071 93.4 0.572
No 868 82.5 92.6
Postoperative chemotherapy None 399 87.9 0.002 92.5 0.318
IV 5-FU/Oral 5-FU 591 78.4 93.6
FOLFOX/FOLFIRI/etc. 93 76.0 89.2
Anastomotic leakage No 1014 82.1 0.016 93.5 0.007
Yes 69 71.7 81.8
5-FU¼ 5-fluorouracil; AR¼ anterior resection with double stapled anastomosis; ASA¼American Society of Anesthesiologists; BMI¼ body mass
index; CAA¼ coloanal anastomosis; CRM¼ circumferential resection margin; DFS ¼ disease-free survival; DRM¼ distal resection margin;
ver
Kang et al Medicine  Volume 94, Number 29, July 2015presentations, which might be a potential limitation of this
study. Second, important clinicopathological factors such as
CRM involvement were not available in whole study popu-
lations. CRM involvement is known to be one of the most
important prognostic factors in rectal cancer.33 Third, the
indications of applying laparoscopic surgery, preoperative che-
LAR¼ low anterior resection with double stapled anastomosis; OS ¼ omoradiotherapy, or making a diverting stoma during the surgery
were left to the discretion of the surgeon. Although this reflects
daily clinical practice, it could cause a selection bias. Finally, in
6 | www.md-journal.comthis study, the 30-day mortality rate was 1.4% in the leakage
group and overall 30-day mortality rate in this cohort was 0.2%.
It is known that the mortality rate after AL ranged from 4% to
18%.3,11,13,34 This result might reflect a recent development of
postoperative care and intensive care unit management. In
addition, our enrolled patients were treated in highly qualified
all survival; TNM ¼ tumor node metastasis.centers for laparoscopic surgery in our nation. Thus, it remains
unanswered that our results are reproducible in general
practice.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 4. Multivariate Analysis of Prognostic Factors
5-yr DFS 5-yr OS
HR (95% CI) P Value HR (95% CI) P Value
Age, yr
70 vs <70 1.4 (1.0–2.0) 0.008 2.1 (1.3–3.5) <0.001
ASA grade
II vs I – – 1.9 (1.2–3.2) 0.007
III vs I – – 1.5 (0.5–4.4) 0.461
Neoadjuvant CRT
Yes vs no 1.4 (1.0–2.0) 0.021 – –
TNM stage
II vs 0 and I 1.2 (0.7–2.0) 0.331 0.7 (0.3–1.6) 0.544
III vs 0 and I 4.3 (2.9–6.4) <0.001 2.8 (1.5–5.0) 0.001
CRM
1 mm vs >1 mm 1.9 (1.1–3.2) 0.011 3.1 (1.6–6.1) 0.013
Unknown vs >1 mm 0.7 (0.5–1.1) 0.187 0.6 (0.3–1.2) 0.217
Anastomotic leakage
Yes vs no 1.6 (1.0–2.6) 0.042 2.1 (1.0–4.2) 0.028
Factors withP< 0.05 in univariate analysis were included in the multivariate analysis. Factors associated with DFS and OS were analyzed by a Cox-
proportional hazards regression analysis done by a forward stepwise selection of variables. ASA¼American Society of Anesthesiologists; CI ¼
hem
Medicine  Volume 94, Number 29, July 2015 Impact of Anastomotic Leakage on Oncologic OutcomesIn conclusion, AL is associated with increased LR and
reduced OS after laparoscopic TME with sphincter preser-
vation. Therefore, surgeons should be more cautious of redu-
cing the AL rate when performing laparoscopic TME.
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